A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit

A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit

Pharmacodynamic analyses were proposed to determine optimal empirical antibiotic therapy against Gram-negative bacteria isolated in a Brazilian ICU. Due to high resistance rates, standard regimens of cefepime, ciprofloxacin, meropenem, and piperacillin/tazobactam were not able to attain significant...

Full description

Bibliographic Details
Main Authors:	Carlos R.V. Kiffer, Joseph L. Kuti, Caio M.F. Mendes, Carmen P. Oplustil, Jorge B. Amarante, Maria L. Biancalana, Nelson Xavier, David P. Nicolau
Format:	Article
Language:	English
Published:	Elsevier
Series:	Brazilian Journal of Infectious Diseases
Subjects:	Pharmacodynamics resistance carbapenem meropenem
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200001&lng=en&tlng=en

Similar Items

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)

Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)
by: Joseph L. Kuti, et al.
Published: (2019-06-01)

Extended or Continuous Infusion of Carbapenems in Children with Severe Infections: A Systematic Review and Narrative Synthesis
by: Pengxiang Zhou, et al.
Published: (2021-09-01)

Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?
by: Silvia Corcione, et al.
Published: (2020-03-01)

Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation
by: Xiangqing Song, et al.
Published: (2019-11-01)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
by: Sonia Luque, et al.
Published: (2021-06-01)

Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study
by: Hui-Ying Zhao, et al.
Published: (2017-01-01)

The stability of carbapenems before and after admixture to PMMA-cement used for replacement surgery caused by Gram-negative bacteria
by: Matthias Schmid, et al.
Published: (2020-08-01)

Carbapenems in clinical practice
by: S.O. Kramarov, et al.
Published: (2019-03-01)

Pharmacokinetic and Pharmacodynamic Modeling of Antibiotics and Bacterial Drug Resistance
by: Syed Mohamed, Ami Fazlin
Published: (2013)

Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003
by: Carlos Kiffer, et al.

Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital
by: Guilherme Henrique Furtado, et al.
Published: (2015-10-01)

CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT
by: I. I. Shteynberg, et al.
Published: (2015-03-01)

Meropenem – therapeutic recommendation after twenty years of presence on pharmaceutical market
by: Magdalena Paczkowska, et al.
Published: (2014-05-01)

Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration Indicações da evolução da resistência ao carbapenem através da heteroresistência como estágio intermediário no Acinetobacter baumannii após administração de carbapenem
by: Silvana Vargas Superti, et al.
Published: (2009-04-01)

Meropenem Administered via Intravenous Regional Limb Perfusion for Orthopedic Sepsis in Horses: A Clinical Retrospective Study
by: Allison P. Mosichuk, et al.
Published: (2021-03-01)

Study Design and Dose Regimen Evaluation of Antibiotics based on Pharmacokinetic and Pharmacodynamic Modelling
by: Kristoffersson, Anders
Published: (2015)

Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients
by: Milan Kaska, et al.
Published: (2018-09-01)

Prevalence of Carbapenem Resistance in Acinetobacter baumannii Isolates from Burn and Non-Burn Patients in Tehran
by: Zahra Ghareboghy Sarmad, et al.
Published: (2015-09-01)

Prevalence of Carbapenem Resistance in Acinetobacter baumannii Isolates from Burn and Non Burn Patients in Tehran
by: Zahra Ghareboghy-Sarmad, et al.
Published: (2015-11-01)

Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms
by: Sarah C. J. Jorgensen, et al.
Published: (2018-10-01)

Population Pharmacokinetics of Vancomycin and Meropenem in Pediatric Extracorporeal Membrane Oxygenation Support
by: Brenda Zylbersztajn, et al.
Published: (2021-08-01)

Carbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing
by: Fred C. Tenover, et al.
Published: (2006-08-01)

In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China
by: Huang N, et al.
Published: (2021-06-01)

Carbapenem-Hydrolyzing Metallo-ß-Lactamase from a Nosocomial Isolate of Pseudomonas aeruginosa in France
by: Laurent Poirel, et al.
Published: (2000-02-01)

Meropenem Resistance among Acinetobacter Positive Clinical Samples in a Tertiary Care Centre in Nepal: A Descriptive Cross-sectional Study
by: Nisha Sharma, et al.
Published: (2021-09-01)

Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study
by: Hessa Al Muqati, et al.
Published: (2021-03-01)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
by: Renata Černá Pařízková, et al.
Published: (2021-07-01)

Degradation of Meropenem by Heterogeneous Photocatalysis Using TiO<sub>2</sub>/Fiberglass Substrates
by: Alejandro Altamirano Briones, et al.
Published: (2020-03-01)

Successful Treatment of Serious Meningitis Caused by Extremely Carbapenem-Resistant Enterobacter cloacae (MIC≥16mg/L) with i.v. Meropenem and i.v. Amikacin Plus Intraventricular Amikacin
by: He Z, et al.
Published: (2019-12-01)

Overview and Insights into Carbapenem Allergy
by: Yuman Lee, et al.
Published: (2019-08-01)

Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
by: Adela Benítez-Cano, et al.
Published: (2020-02-01)

The Susceptibility Evaluation of Multiresistant Gram-Negative Bacilli to Meropenem and Imipenem
by: Nematollah Jonidi Jafari, et al.
Published: (2014-03-01)

Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance Utilização de princípios de farmacocinética e farmacodinâmica na otimização do tratamento antimicrobiano com relação à resistência emergente
by: Lauro Santos Filho, et al.
Published: (2007-06-01)

Identifying “at-risk” patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections
by: Mohd H. Abdul-Aziz, et al.
Published: (2017-11-01)

Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia
by: Nada A Alsaleh, et al.
Published: (2020-11-01)

Cerebrospinal fluid penetration of very high-dose meropenem: a case report
by: Thomas Kerz, et al.
Published: (2018-12-01)

Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts
by: Satoshi Hamanoue, et al.
Published: (2018-10-01)

Carbapenemases from the Laboratory to the Clinic in Gram-Negative Enteric Bacteria
by: Sinem BUDAK, et al.
Published: (2012-12-01)

In vitro activity of ceftolozane–tazobactam and ceftazidime–avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study
by: Hasan Cenk Mirza, et al.
Published: (2020-03-01)